Pan-Genotypic DAA Regimens Safe, Effective for Children, Adolescents with Chronic HCV
Results of the systematic review and meta-analysis support the use of pan-genotypic DAA regimens for the treatment of chronic HCV in adolescents and children ≥ 3 years of age.
Source: hcplive.com